Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWRBiotechnology
+$4.49 today
- Market cap
- $6.09B
- Beta
- 1.27
- P/E (TTM)
- -38.4
- EPS (TTM)
- -$2.11
Volume 2.42M
Average 1.82M
ARWR Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR
Operating Expenses · Q4 FY2026 · quarter ended Sep 2026
Operating expenses growth accelerates
Q4 FY2026 operating expenses of $472.62M rose 122.6% year over year, ahead of the +58.1% change in trailing-twelve-month operating expenses. Sequentially, it rose 92.6% from the prior quarter. Over 3 fiscal years it compounded at +38.7% a year.
Context
- Operating expenses amounted to 256.5% of revenue in FY2026, up 168.3 pp from a year earlier.
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +122.6% holds above the trailing-twelve-month pace of +58.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2026
- 1.16B USD
- Year-over-year change
- +58.1%
- 4-year CAGR
- +29.5%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2026 | 2026-09-30 | 1.16B | +58.1% |
| FY2025 | 2025-09-30 | 731.1M | +24.8% |
| FY2024 | 2024-09-30 | 586.04M | +35.3% |
| FY2023 | 2023-09-30 | 433.24M | +5.3% |
| FY2022 | 2022-09-30 | 411.32M | — |
Operating Expenses vs competitors
How ARWR compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +58.1% is the highest of 6, against a peer median of +15.6%.
- Operating expenses amounts to 256.5% of revenue for ARWR, versus a peer median of 327.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.83B USD | +26.4% | +15.3% | 58.9% | |
| LTM Sep 2026 | $1.51B USD | +22.3% | +10.0% | 157.1% | |
| LTM Sep 2026 | $1.16B USD | +58.1% | +38.7% | 256.5% | |
| LTM Mar 2026 | $264.22M USD | +15.6% | +14.4% | 368.0% | |
| LTM Mar 2026 | $130.57M USD | -39.9% | -10.4% | 287.9% | |
| LTM Mar 2026 | $87.2M USD | — | +16.9% | 9463.1% | |
| LTM Mar 2026 | €58.51M EUR | +12.1% | -7.3% | 435.3% | |
| Peer median (excluding ARWR) | — | +15.6% | +12.2% | 327.9% | |
Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 | FY2026 Sep 2026 |
|---|---|---|---|---|---|
| Revenue | 243.23M | 240.74M | 3.55M | 829.45M | 450.82M |
| Cost of Revenue | 10.42M | 12.49M | 18.6M | 0 | 1.8M |
| Gross Profit | 232.81M | 228.24M | (15.04M) | 829.45M | 449.02M |
| Gross Margin | 95.7% | 94.8% | -423.7% | 100.0% | 99.6% |
| Research & Development | 288.5M | 342.31M | 489.22M | 607.16M | 739.14M |
| Selling, General & Admin | 124.43M | 90.93M | 96.82M | 121.92M | 202.05M |
| Operating Expenses | 411.32M | 433.24M | 586.04M | 731.1M | 1.16B |
| Depreciation & Amortization | 10.42M | 12.49M | 18.6M | 23.93M | 26.62M |
| EBITDA | (162.29M) | (175.67M) | (561.51M) | 164.82M | (603.59M) |
| EBITDA Margin | -66.7% | -73.0% | -15812.8% | 19.9% | -133.9% |
| Operating Income | (178.51M) | (205M) | (601.08M) | 98.35M | (707.17M) |
| Operating Margin | -73.4% | -85.2% | -16927.1% | 11.9% | -156.9% |
| Interest Income | 5.03M | 15.3M | 22.72M | 37.29M | 57.86M |
| Interest Expense | 0 | 18.33M | 32.35M | 89.36M | 93.71M |
| Other Income / Expenses | 5.8M | (1.49M) | (11.38M) | (46.81M) | (16.74M) |
| Income Before Tax | (172.71M) | (206.49M) | (612.46M) | 51.53M | (723.92M) |
| Pre-Tax Margin | -71.0% | -85.8% | -17247.5% | 6.2% | -160.6% |
| Income Tax Expense | 3.79M | 2.78M | (2.77M) | 21.42M | (6.78M) |
| Net Income | (176.06M) | (205.28M) | (599.49M) | (1.63M) | (724.21M) |
| Net Margin | -72.4% | -85.3% | -16882.4% | -0.2% | -160.6% |
| EPS (Basic) | (1.67) | (1.92) | (5.00) | (0.01) | (5.11) |
| EPS (Diluted) | (1.67) | (1.92) | (5.00) | (0.01) | (5.11) |
| Weighted Avg Shares | 105.43M | 106.75M | 119.78M | 133.76M | 141.63M |
| Weighted Avg Shares (Diluted) | 105.43M | 106.75M | 119.78M | 133.76M | 141.63M |
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
Intrinsic Alpha fair value
Locked
Current Price
$43.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.